Rubius Therapeutics
Cambridge, Massachusetts, United States
About Rubius Therapeutics
Rubius Therapeutics is creating RCTs™ as a new class of medicines. Leading applications include programs in cancer, enzyme deficiency diseases and the induction of tolerance to treat autoimmune disease. The company was conceived and launched by Flagship VentureLabs®, the innovation foundry where a team of scientific entrepreneurs systematically evolve enterprising ideas based upon previously undiscovered areas of science into real-world inventions and ventures.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Total funding: $445.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2021)
- Ticker: nasdaq:RUBY
- Website: rubiustx.com
- Phone: (617)218-1606
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/rubius-therapeutics-2248311 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.